Core Viewpoint - The stock of TEBIO experienced a decline of 2.06% on October 16, 2023, with a trading volume of 1.40 billion yuan and a market capitalization of 31.974 billion yuan [1] Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion yuan, representing a year-on-year growth of 26.96%, and a net profit attributable to shareholders of 428 million yuan, which is a 40.60% increase compared to the previous year [2] Shareholder and Market Activity - As of June 30, 2025, TEBIO had 8,439 shareholders, an increase of 13.00% from the previous period, with an average of 48,204 circulating shares per shareholder, down by 11.51% [2] - The stock's performance shows an 8.04% increase year-to-date, but a decline of 3.44% over the last five trading days and 3.99% over the last twenty days [1] Dividend Distribution - TEBIO has distributed a total of 577 million yuan in dividends since its A-share listing, with 506 million yuan distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included the Huaxia SSE STAR 50 ETF, which increased its holdings by 837,500 shares, and the E Fund SSE STAR 50 ETF, which added 189,900 shares [3]

Core Viewpoint - The innovation drug sector in China is experiencing significant growth, driven by increased investment, favorable policies, and a strong pipeline of new drugs entering clinical trials, positioning it for a robust future in both domestic and international markets [6][8][10]. Group 1: Market Performance - As of October 16, the Science and Technology Innovation Drug ETF (Huitianfu, 589120) saw a notable increase of 3.31%, maintaining a rise of over 2% despite a slight pullback [1]. - The ETF has attracted over 40 million yuan in net inflows over the past five days, indicating strong investor interest [1]. - Key constituent stocks such as Sangfor Technology and Yifang Bio have shown significant gains, with Sangfor hitting the daily limit up and Yifang Bio rising by 8.61% [2][3]. Group 2: Industry Trends - The number of License-out transactions in China reached 72 in the first half of 2025, surpassing half of the total for 2024, with a total transaction value 16% higher than the previous year [5]. - The innovation drug sector is primarily driven by business development (BD) expectations, with a significant portion of annual BD activity occurring in the fourth quarter [6]. - The Chinese innovation drug market is expected to see a recovery in confidence as more BD deals materialize, particularly as companies prepare for the upcoming European Society for Medical Oncology (ESMO) conference [6][7]. Group 3: R&D and Financial Outlook - Since 2015, Chinese innovation drug companies have significantly increased R&D investments, leading to a rise in the number of original innovative drugs entering clinical trials, with 704 drugs expected to enter Phase I trials in 2024 [8]. - The revenue of innovation drug companies has been steadily increasing, with projections indicating that one-third of these companies will achieve profitability by 2025, and 70% will reach breakeven by 2026 [8]. - The Chinese government's support for innovation drugs through favorable policies and increased funding is expected to enhance the sector's growth, with healthcare spending on innovation drugs projected to rise from 50 billion yuan in 2022 to 120 billion yuan in 2024 [9]. Group 4: Competitive Landscape - The impending patent cliff for multinational corporations (MNCs) is expected to create a demand for new products, with 190 drugs losing patent protection by 2030, including 69 with annual sales exceeding 1 billion dollars [10]. - Chinese innovation drug companies are well-positioned to fill this gap due to their high R&D efficiency and rich technological outcomes, making them attractive partners for MNCs [10].

Group 1 - The core point of the news is that TEBIO conducted a block trade on October 14, with a transaction volume of 46,500 shares and a total transaction amount of 3.76 million yuan, at a price of 80.92 yuan per share [1][2] - The buyer of the block trade was Guotai Junan Securities Co., Ltd. headquarters, while the seller was GF Securities Co., Ltd. Xiamen Hubin South Road Securities Business Department [1][2] - In the last three months, TEBIO has had a total of 11 block trades, with a cumulative transaction amount of 80.79 million yuan [1][2] Group 2 - As of October 14, TEBIO's closing price was 80.92 yuan, reflecting a decrease of 3.54%, with a daily turnover rate of 0.83% and a total trading volume of 276 million yuan [1][2] - The net inflow of main funds for the day was 4.21 million yuan, and over the past five days, the stock has seen a cumulative decline of 3.41% with a total net inflow of 1.33 million yuan [1][2] - The latest margin financing balance for TEBIO is 1.477 billion yuan, which has increased by 5.19 million yuan over the past five days, representing a growth of 0.35% [2]

Group 1 - The company, TeBao Bio, executed a block trade of 46,500 shares on October 14, with a transaction value of 3.7604 million yuan [1] - This transaction accounted for 1.35% of the total trading volume on that day [1] - The transaction price was 80.92 yuan, which was flat compared to the market closing price of 80.92 yuan [1]

Investment Rating - The industry investment rating is "Overweight (Maintain)" [1] Core Viewpoints - The report highlights significant advancements in the hepatitis B treatment sector, with innovative drugs like GST-HG131 and Peginterferon being recognized for their clinical efficacy and market potential [6][4] - The global hepatitis B infection rate is concerning, with 254 million chronic infections reported in 2022, indicating a substantial market opportunity for effective treatments [4] - The Chinese government's action plan aims to enhance diagnosis and treatment rates for hepatitis B, which is expected to further drive market growth [5] Summary by Sections Industry Overview - The pharmaceutical and biotechnology industry is currently focused on hepatitis B treatments, with a notable increase in research and development efforts [1][6] Recent Developments - Guangsheng Tang's innovative drug GST-HG131 has been accepted for presentation at the American Association for the Study of Liver Diseases, marking a significant recognition in the field [3][4] - The approval of new indications for Peginterferon by TEBIO enhances its competitive position in the market [3][6] Market Potential - The report emphasizes the vast market potential for hepatitis B treatments, with current diagnosis and treatment rates in China at only 22% and 15% respectively, suggesting significant room for improvement [4][5] - The government's action plan sets ambitious targets for reducing hepatitis B prevalence and increasing treatment rates by 2030, which could lead to a more favorable market environment for pharmaceutical companies [5]

Core Viewpoint - The stock of TEBIO experienced a decline of 2.00% on October 14, with a current price of 82.21 CNY per share and a market capitalization of 33.443 billion CNY. The company has seen a year-to-date stock price increase of 13.00% but has faced a slight decline in the recent trading periods [1]. Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion CNY, representing a year-on-year growth of 26.96%. The net profit attributable to shareholders was 428 million CNY, showing a year-on-year increase of 40.60% [2]. - Since its A-share listing, TEBIO has distributed a total of 577 million CNY in dividends, with 506 million CNY distributed over the past three years [3]. Shareholder and Market Activity - As of June 30, 2025, TEBIO had 8,439 shareholders, an increase of 13.00% from the previous period. The average number of circulating shares per shareholder decreased by 11.51% to 48,204 shares [2]. - The major shareholders include ETFs such as 华夏上证科创板50成份ETF and 易方达上证科创板50ETF, which have increased their holdings [3]. Company Overview - TEBIO, established on August 7, 1996, and listed on January 17, 2020, is based in Xiamen, Fujian Province. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with a revenue composition of 86.85% from antiviral drugs and 12.87% from blood/cancer drugs [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the biopharmaceuticals category [1].

每经AI快讯，10月13日，特宝生物(688278.SZ)公告，公司产品派格宾联合核苷(酸)类似物用于成人慢性 乙型肝炎患者HBsAg持续清除的增加适应症已获国家药监局批准。此次获批基于临床试验结果，显示 31.4%患者在停药24周后实现HBsAg转阴且HBVDNA持续抑制。该适应症拓展显著提升派格宾市场潜 力，强化其在慢乙肝临床治愈领域的地位。 ...

受理号：CXSS2400023、CXSS2400024、CXSS2400025、CXSS2400026 证书编号：2025S03097、2025S03098、2025S03099、2025S03100 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 近日，厦门特宝生物工程股份有限公司（以下简称"公司"）收到国家药品监督管理局核准签发的《药品 注册证书》，公司产品派格宾联合核苷（酸）类似物用于成人慢性乙型肝炎患者的HBsAg持续清除的增 加适应症（以下简称"增加适应症"）上市许可申请获得批准。现将有关情况公告如下： 一、药品基本情况 药品名称：派格宾? 通用名称：聚乙二醇干扰素α-2b注射液 申请事项：药品注册（境内生产） 我国2022版《慢性乙型肝炎防治指南》中指出："对于部分适合条件的患者，应追求临床治愈（又称功 能性治愈）"，即停止所有治疗药物6个月或更长时间HBsAg持续清除伴HBV DNA持续抑制。HBsAg持 续清除是一个重要的临床治疗目标，目前被认为是获得HBV功能性治愈的标志。本次派格宾获批增加 适应症是基于一 ...

Core Viewpoint - The approval of the expanded indication for Pegbiv, a drug developed by Xiamen Tebao Biological Engineering Co., Ltd., marks a significant advancement in the treatment of chronic hepatitis B, enhancing its market competitiveness and potential for clinical cure [1][5]. Drug Basic Information - Drug Name: Pegbiv - Generic Name: Pegylated Interferon α-2b Injection - Application: Drug registration (domestic production) - Approval Conclusion: The drug is approved for use in adults with chronic hepatitis B for HBsAg clearance when used in combination with nucleos(t)ide analogs [1][2]. Drug Background - Pegbiv is the company's core product and the world's first 40kD pegylated long-acting interferon α-2b injection, classified as a Category 1 new drug in China. It was first approved for chronic hepatitis C in October 2016 and for chronic hepatitis B in September 2017 [2]. Chronic Hepatitis B Context - Chronic hepatitis B is a significant public health issue in China, with an estimated 75 million infected individuals as of 2020. The prevalence of HBsAg has decreased from 9.72% in 1992 to 5.86% in 2020 [3]. The disease poses risks of liver failure, cirrhosis, and liver cancer [3]. Clinical Cure Concept - The 2022 Chronic Hepatitis B Prevention and Treatment Guidelines in China emphasize the pursuit of clinical cure, defined as sustained HBsAg clearance and HBV DNA suppression after stopping all treatment for six months or longer [4]. The approval of Pegbiv's expanded indication is based on clinical trial results demonstrating its efficacy in achieving these treatment goals [4][5]. Clinical Trial Results - In a clinical trial, 31.4% of patients achieved HBsAg clearance and sustained HBV DNA suppression 24 weeks after treatment cessation, providing strong evidence for Pegbiv's role in achieving clinical cure for chronic hepatitis B [5].

派格宾是公司目前的核心产品，是公司自主研发的全球首个40kD聚乙二醇长效干扰素α-2b注射液，是 治疗用生物制品国家1类新药，是我国第一个国产上市的聚乙二醇(PEG)修饰干扰素品种。派格宾于 2016年10月获批上市，获批适应症为治疗成人慢性丙型肝炎;2017年9月获批成人慢性乙型肝炎适应症。 特宝生物(688278.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《药品注册证书》， 公司产品派格宾联合核苷(酸)类似物用于成人慢性乙型肝炎患者的HBsAg持续清除的增加适应症(简 称"增加适应症")上市许可申请获得批准。 ...